IO Biotech, Inc. updated its corporate presentation for the Oppenheimer 33rd Annual Healthcare Conference, disclosing that it had approximately $142 million of cash and cash equivalents as of December 31, 2022 and confirming its projected cash runway through the third quarter of 2024.